Tree-in-bud Pattern in ALK-positive Lung Adenocarcinoma

od Shiroyama, Takayuki, Nasu, Shingo, Tanaka, Ayako, Hirashima, Tomonori
izdano v Intern Med (2020)

Important factors for achieving survival of five years or more in non-small cell lung cancer patients with distant metastasis

od HIRASHIMA, TOMONORI, SUZUKI, HIDEKAZU, OKAMOTO, NORIO, MORISHITA, NAOKO, YAMADORI, TADAHIRO, TAMIYA, MOTOHIRO, SHIROYAMA, TAKAYUKI, KURATA, KANAKO, KAWASE, ICHIRO
Izdano 2014

The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutations

od Suzuki, Hidekazu, Hirashima, Tomonori, Okamoto, Norio, Yamadori, Tadahiro, Tamiya, Motohiro, Morishita, Naoko, Shiroyama, Takayuki, Otsuka, Tomoyuki, Kitai, Kanako, Kawase, Ichiro
Izdano 2013

Chemotherapy for patients with advanced lung cancer receiving long-term oxygen therapy

od Hayama, Manabu, Suzuki, Hidekazu, Shiroyama, Takayuki, Tamiya, Motohiro, Okamoto, Norio, Tanaka, Ayako, Morishita, Naoko, Nishida, Takuji, Nishihara, Takashi, Hirashima, Tomonori
izdano v J Thorac Dis (2016)

Successful retreatment with osimertinib after osimertinib-induced acute pulmonary embolism in a patient with lung adenocarcinoma: A case report

od Shiroyama, Takayuki, Hayama, Manabu, Satoh, Shingo, Nasu, Shingo, Tanaka, Ayako, Morita, Satomu, Morishita, Naoko, Suzuki, Hidekazu, Okamoto, Norio, Hirashima, Tomonori
izdano v Respir Med Case Rep (2016)

Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma

od Satoh, Shingo, Shiroyama, Takayuki, Tamiya, Motohiro, Nasu, Shingo, Tanaka, Ayako, Morita, Satomu, Morishita, Naoko, Suzuki, Hidekazu, Okamoto, Norio, Hirashima, Tomonori
izdano v Respir Med Case Rep (2017)

The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC

od Tamiya, Motohiro, Tamiya, Akihiro, Okamoto, Norio, Taniguchi, Yoshihiko, Nishino, Kazumi, Atagi, Shinji, Hirashima, Tomonori, Imamura, Fumio, Kumagai, Toru, Suzuki, Hidekazu
izdano v Sci Rep (2021)

A heterochronic genetic change from an EGFR mutation to an ALK rearrangement in a patient with lung adenocarcinoma: a case report

od Shiroyama, Takayuki, Tamiya, Motohiro, Hayama, Manabu, Nishihara, Takashi, Nishida, Takuji, Tanaka, Ayako, Morishita, Naoko, Suzuki, Hidekazu, Okamoto, Norio, Kawahara, Kunimitsu, Hirashima, Tomonori
izdano v J Thorac Dis (2016)

Osimertinib Treatment Was Unsuccessful for Lung Adenocarcinoma with G719S, S768I, and T790M Mutations

od Nasu, Shingo, Shiroyama, Takayuki, Morita, Satomu, Takata, So, Takada, Hiromune, Masuhiro, Kentaro, Tanaka, Ayako, Morishita, Naoko, Suzuki, Hidekazu, Okamoto, Norio, Hirashima, Tomonori
izdano v Intern Med (2018)

Association Between Imaging Findings of Airway Obstruction Adjacent to Lung Tumors and the Onset of Interstitial Lung Disease After Nivolumab

od NAKAHAMA, KENJI, TAMIYA, AKIHIRO, ISA, SHUN-ICHI, TANIGUCHI, YOSHIHIKO, SHIROYAMA, TAKAYUKI, SUZUKI, HIDEKAZU, INOUE, TAKAKO, TAMIYA, MOTOHIRO, HIRASHIMA, TOMONORI, IMAMURA, FUMIO, ATAGI, SHINJI
izdano v In Vivo (2018)

Carboplatin plus paclitaxel in combination with bevacizumab for the treatment of adenocarcinoma with interstitial lung diseases

od SUZUKI, HIDEKAZU, HIRASHIMA, TOMONORI, KOBAYASHI, MASASHI, OKAMOTO, NORIO, MATSUURA, YUKA, TAMIYA, MOTOHIRO, MORISHITA, NAOKO, OKAFUJI, KOHEI, SHIROYAMA, TAKAYUKI, MORIMURA, OSAMU, MORITA, SATOMU, KAWASE, ICHIRO
Izdano 2013

Prospective phase II study of cisplatin plus pemetrexed with maintenance of pemetrexed for advanced non-squamous cell non-small cell lung cancer in Japan

od Asami, Kazuhiro, Kawahara, Masaaki, Hirashima, Tomonori, Suzuki, Hidekazu, Okishio, Kyoichi, Omachi, Naoki, Tamiya, Motohiro, Tamiya, Akihiro, Hirooka, Aya, Nakao, Keiko, Tsuji, Taisuke, Atagi, Shinji
izdano v Thorac Cancer (2014)

Radial endobronchial ultrasound with a guide sheath for diagnosis of peripheral cavitary lung lesions: a retrospective study

od Hayama, Manabu, Okamoto, Norio, Suzuki, Hidekazu, Tamiya, Motohiro, Shiroyama, Takayuki, Tanaka, Ayako, Nishida, Takuji, Nishihara, Takashi, Uehara, Nobuko, Morishita, Naoko, Kawahara, Kunimitsu, Hirashima, Tomonori
izdano v BMC Pulm Med (2016)

Transformation to small cell lung cancer after first-line afatinib treatment

od Shiroyama, Takayuki, Nasu, Shingo, Tanaka, Ayako, Takata, So, Masuhiro, Kentaro, Takada, Hiromune, Morita, Satomu, Morishita, Naoko, Suzuki, Hidekazu, Okamoto, Norio, Kawahara, Kunimitsu, Hirashima, Tomonori
izdano v Respir Med Case Rep (2018)

Re-challenge chemotherapy in patients with sensitive relapse small-cell lung cancer and interstitial lung disease

od Nasu, Shingo, Suzuki, Hidekazu, Moriizumi, Kazunori, Hara, Yuki, Tanaka, Satoshi, Takada, Hiromune, Morita, Satomu, Tanaka, Ayako, Shiroyama, Takayuki, Morishita, Naoko, Okamoto, Norio, Hirashima, Tomonori
izdano v J Thorac Dis (2019)

A Phase II Study of Tailored-dose S-1 Plus Carboplatin Followed by Maintenance S-1 for Advanced Squamous Cell Lung Cancer: OSAKA-LCSG 1102

od Yokoi, Takashi, Minami, Seigo, Shiroyama, Takayuki, Koba, Taro, Torii, Yoshitaro, Sugimoto, Hiroyuki, Niki, Maiko, Mori, Masahide, Morimura, Osamu, Hirashima, Tomonori, Komuta, Kiyoshi, Kijima, Takashi
izdano v Intern Med (2019)

Effectiveness of EGFR tyrosine kinase inhibitors in advanced non‐small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study

od Kanazu, Masaki, Mori, Masahide, Kimura, Madoka, Nishino, Kazumi, Shiroyama, Takayuki, Nagatomo, Izumi, Ihara, Shoichi, Komuta, Kiyoshi, Suzuki, Hidekazu, Hirashima, Tomonori, Kumagai, Toru, Imamura, Fumio
izdano v Thorac Cancer (2020)

Relationship between the Pharmacokinetics of Irinotecan and Diarrhea during Combination Chemotherapy with Cisplatin

od Kudoh, Shinzoh, Fukuoka, Masahiro, Masuda, Noriyuki, Yoshikawa, Atsuko, Kusunoki, Yoko, Matsui, Kaoru, Negoro, Shun‐ichi, Takifuji, Nobuhide, Nakagawa, Kazuhiko, Hirashima, Tomonori, Yana, Takashi, Takada, Minoru
izdano v Jpn J Cancer Res (1995)

Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group

od Murakami, Haruyasu, Yamanaka, Takeharu, Seto, Takashi, Sugio, Kenji, Okamoto, Isamu, Sawa, Toshiyuki, Hirashima, Tomonori, Takeda, Koji, Atagi, Shinji, Fukuoka, Masahiro, Nakanishi, Yoichi, Nakagawa, Kazuhiko, Yamamoto, Nobuyuki
izdano v Cancer Sci (2014)

Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer

od Nakao, Keiko, Kobuchi, Shinji, Marutani, Shuhei, Iwazaki, Ayano, Tamiya, Akihiro, Isa, Shunichi, Okishio, Kyoichi, Kanazu, Masaki, Tamiya, Motohiro, Hirashima, Tomonori, Imai, Kimie, Sakaeda, Toshiyuki, Atagi, Shinji
izdano v Sci Rep (2019)